Solna,
Data from ADME studies (Absorption, Distribution, Metabolism, and Excretion) and secondary pharmacology studies confirm that Cantrixil has suitable physicochemical properties and an acceptable safety profile with minimal off-target effects, supporting continued development in bladder and blood cancer indications. Additional in vitro and in vivo studies are planned during 2024 to ensure the properties, safety and efficacy of the drug before proceeding to clinical trials.
“These supplementary studies provide essential information about Cantrixil and build upon earlier pharmacological and toxicological studies that are included in the preclinical evaluation required by the regulatory authorities. We are now looking forward to continuing the development of Cantrixil and preparing for clinical studies in these hard-to-treat cancer indications,” said
The preclinical data package for Cantrixil is currently being extended as bladder and blood cancers are indications that require routes of drug administration not investigated previously. Both bladder and blood cancer have high unmet medical needs and significant commercial potential.
About Cantrixil
Cantrixil is a drug candidate being developed for the treatment of late-stage cancer and consists of the active molecule TRX-E-002-1, a potent third generation benzopyran, encapsulated in a cyclodextrin. Cantrixil targets a wide spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells (cancer stem cells) that are thought to be responsible for disease recurrence.
To maximize the commercial potential of the Cantrixil program,
For more information:
Phone: +46 018-50 54 40
E-mail: IR@vivesto.com
About
Vivesto’s most advanced program Apealea® (paclitaxel micellar) has been granted market approval in the EU as a treatment for adult patients suffering from the first relapse of platinum sensitive epithelial ovarian cancer, or primary peritoneal cancer or fallopian tube cancer. In addition,
Vivesto’s shares are traded on Nasdaq Stockholm (ticker: VIVE). Visit www.vivesto.com for more information about
© Modular Finance, source